Skip to main content
Premium Trial:

Request an Annual Quote

Labcorp NGS Test for Identifying SARS-CoV-2 Strains Receives FDA EUA

NEW YORK – The US Food and Drug Administration announced after the close of the markets on Friday that it has issued Emergency Use Authorization (EUA) for Laboratory Corporation of America's VirSeq SARS-CoV-2 NGS Test.

The test uses the PacBio Sequel II NGS system and is intended to identify specific SARS-CoV-2 strains in patient samples identified as SARS-CoV-2 positive using Labcorp’s COVID-19 RT-PCR Test or its SARS-CoV-2 & Influenza A/B Assay when a healthcare provider believes that strain-specific information could help guide appropriate patient care. The test, the FDA said in its authorization letter, is not to aid in the primary diagnosis of SARS-CoV-2 infection or to confirm the presence of infection with the virus. Nor is it to identify specific SARS-CoV-2 genomic mutations.

The test, which uses respiratory samples, is the first to receive FDA EUA for identification and differentiation of SARS-CoV-2 strains. It can be performed at Labcorp laboratories designated under CLIA as meeting the requirements to perform high-complexity testing.

The Scan

Monkeypox Meeting

As the World Health Organization gets ready to hold another monkeypox meeting, the US distributes vaccines and increases its testing capacity.

CRISPR's Softer Side

A homologous chromosome-templated repair approach to gene editing relies on versions of the Cas9 enzyme that cut a single DNA strand.

Pickled? No Problem

Researchers come up with an approach for extracting DNA from archived museum specimens. 

Nature Papers on Long Reads for Bacterial Genomes, Zebrafish Atlas, Hypothalamic Aging in Mammals

In Nature this week: near-finished microbial genomes without polishing, zebrafish functional annotation program, and more.